Family Management Corp Beam Therapeutics Inc. Transaction History

Family Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $994 - $1,757	-25 Reduced 0.44%	5,690 $271,000
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $101,673 - $212,335	-3,405 Reduced 37.34%	5,715 $221,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $243,919 - $355,229	3,586 Added 64.8%	9,120 $727,000
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $56,274 - $89,111	667 Added 13.7%	5,534 $482,000
Q2 2021 Aug 13, 2021	BUY	$64.12 - $128.71 $312,072 - $626,431	4,867 New	4,867 $626,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Family Management Corp, based on Form 13F filings with the SEC.

Stay updated on Family Management Corp with notifications on news.